Purpose:To evaluate survival outcomes and identify prognostic factors among bladder cancer patients. Patients and Methods:A total of 488 bladder cancer patients admitted between 2007 and 2017 were followed until December 31, 2020, using both active and passive follow-up. The Kaplan-Meier method was used to estimate observed survival (OS), with group comparisons performed using the Log rank test. Variables included sex, age group, number of hospital admissions, TNM stage, and geographic origin. Results:Of 488 patients, 485 (99.38%) were successfully followed. The majority were male (80.21%) with a mean age of 66.5 years. The average number of hospital admissions was 1.81. Overall 1-, 3-, 5-, and 10-year OS rates were 79.95%, 63.50%, 56.32%, and 45.54% for males, and 69.79%, 58.33%, 56.01%, and 56.01% for females, respectively (P = 0.697). Age significantly affected prognosis (P < 0.01), with 5-year OS declining from 66.67% (age ≤34) to 29.53% (≥80). Patients with ≥3 admissions had worse survival (44.87%) than those with one (61.93%) or two admissions (58.97%) (P < 0.01). TNM stage was strongly with survival: 5-year OS rates were 86.43% (Stage I), 55.48% (Stage II), 38.25% (Stage III), and 13.85% (Stage IV) (P < 0.01). Regional differences were not statistically significant (P > 0.05). Conclusion:Advanced age and late-stage diagnosis were associated with poorer survival, while early-stage detection correlated with better outcomes. These findings underscore the importance of early screening, timely treatment, and comprehensive care strategies to improve bladder cancer survival, especially in resource-limited settings. Limitations include single-center design and absence of multivariate adjustment.

Aim: The aim of this meta-analysis was to investigate the relationship between the baseline systemic immune inflammatory index (SII) and prognosis in patients with NSCLC. Materials & methods: The relation between pretreatment SII and overall survival, disease-free survival, cancer-specific survival, progression-free survival and recurrence-free survival in NSCLC patients was analyzed combined with hazard ratio and 95% CI. Results: The results showed that high SII was significantly correlated with overall survival and progression-free survival of NSCLC patients, but not with disease-free survival, cancer-specific survival and recurrence-free survival. Conclusion: The study suggests that a higher SII has association with worse prognosis in NSCLC patients.PROSPERO registration number: CRD42022336270.

Objective To analyze the survival status of inpatients with cervical cancer registered in Nantong admitted in Nantong Cancer Hospital from 2002 to 2017. Methods Inpatients with cervical cancer in Nantong Cancer Hospital were followed up from 2017 until December 31, 2020 using active and passive methods to determine their survival outcome. The rate of follow-up loss was statistically analyzed by Chi-square test, the observed survival rate for each year was calculated using the life table, the survival curve was drawn with R language, and the survival rates of patients in different age groups and from different regions were compared with log-rank test (Mantel-Cox). Results A total of 5645 cervical cancer cases were registered. Among them, the survival outcome was recorded for 5512 cases. The success rate of follow-up was 97.64%, and the loss of follow-up rate was 2.36%. The average age of onset was 56.67±12.78 years. The median survival time was 6.54 years, and the 1-, 3-, 5-, and 10-year observed survival rates were 91.50%, 76.95%, 60.99%, and 28.51%, respectively. Among the age groups, significant differences in survival rate were observed between the 15- and 60-year-old groups (χ2=7.469, P=0.006) and between the 15- and 80-year-old groups (χ2=36.317, P < 0.001). No significant difference in survival rate was found between patients from Haimen and Qidong (χ2=2.779, P=0.095) and between patients from Qidong and Tongzhou (χ2=0.515, P=0.473). Significant difference in survival rate was observed among other regions (P < 0.05). Conclusion In this study group, the survival rates of hospital-based patients with cervical cancer significantly differ among the age groups and regions of origin and significantly decreased with age. The high follow-up rate fully reflects the comprehensive effect of the treatment in Nantong Cancer Hospital for registered patients with cervical cancer in Nantong.

Objective:This study aimed to provide a realistic observation of survival by major site for 48,866 cancer patients treated at a tertiary cancer hospital in a rural area of China. Methods:Patients with cancer registered between 2007 and 2017 in the Nantong rural area were followed up. The starting date for survival calculation was the date of the first diagnosis of cancer at the Nantong Tumor Hospital, and the closing date was December 31, 2020. Observed survival (OS) was analyzed according to ICD-10 site, sex, age, region, and hospitalization period using the life table method and compared using the Wilcoxon (Gehan) statistic. Results:The overall 5-year OS rate was 40.48% for all 48,866 patients, 30.19% for males, and 51.90% for females. The top five cancer sites, accounting for 60.51% of the total cases, were the esophagus, lung, stomach, liver, and cervix, with 5-year OS rates of 33.72%, 18.64%, 32.10%, 19.04%, and 71.51%, respectively. The highest 5-year OS was observed in the thyroid (87.52%) and the lowest was in the pancreas (6.37%). Survival was significantly higher in younger patients than in older patients, with 5-year OSs of 69.26% and 19.84% in those aged 20-29 and 90-99 years, respectively. Five-year OSs improved significantly from 39.35% in 2007-2011 to 41.26% in 2012-2017. Conclusion:Overall survival improved over the years, although the improvement at some sites was not significant. The observed survival varies from region to region, reflecting differences in the patterns of major sites, disparities in proportions of hospitalization, and demographic characteristics.

目的 了解1972-2016年启东市老年人群恶性肿瘤发病现状及时间趋势,为制定老年恶性肿瘤精准防控策略提供科学依据.方法 资料来源于启东癌症登记报告系统,提取1972-2016年≥60岁老年人群的恶性肿瘤发病数据.分别计算粗发病率,分时期、年龄别发病率以及世界人口标化率(世标率),采用Joinpoint 4.7.0.0软件计算发病率的年度变化百分比(APC)和平均年度变化百分比(AAPC).结果 1972-2016年启东市老年恶性肿瘤发病66 386例,粗发病率为854.48/10万(男性为1 157.26/10万,女性为603.10/10万),世标率为809.42/10万(男性为1 112.04/10万,女性为558.49/10万),男性粗发病率及世标率均高于女性(P＜0.05).发病率随年龄的增加而呈上升趋势,在75～79岁年龄组达到发病率高峰.1972-2016年,肺癌、胃癌、肝癌、结直肠癌和食管癌是启东市老年人群发病常见肿瘤,约占全部老年恶性肿瘤发病的73.43％,肺癌和胃癌分别是老年男性和老年女性发病第1位的恶性肿瘤.1972-1986年与1987-2001年发病前3位恶性肿瘤均为胃癌、肺癌和肝癌,而到了 2002-2016年时,肺癌跃居发病第1位,肝癌升至第2位,胃癌退居第3位.1972-2016年启东市老年人总人群、男性和女性恶性肿瘤发病世标率均呈上升趋势,AAPC分别为1.39％、1.29％和1.48％(P＜0.01),其中以2002-2016年上升趋势尤为显著(总人群、男性和女性的APC分别为4.94％、4.34％、6.29％,P＜0.01).结论 启东市老年人群恶性肿瘤发病不断升高,尤以2002年以来增速明显,肺癌、胃癌、肝癌、结直肠癌和食管癌为启东市老年人群发病常见恶性肿瘤.老年男性应是启东市老年恶性肿瘤防控重点人群.

BackgroundCancer survival is an important indicator for evaluating cancer prognosis and cancer care outcomes. The incidence dates used in calculating survival differ between population-based registries and hospital-based registries. Studies examining the effects of the left truncation of incidence dates and delayed reporting on survival estimates are scarce in real-world applications.MethodsCancer cases hospitalized at Nantong Tumor Hospital during the years 2002–2017 were traced with their records registered in the Qidong Cancer Registry. Survival was calculated using the life table method for cancer patients with the first visit dates recorded in the hospital-based cancer registry (HBR) as the diagnosis date (OSH), those with the registered dates of population-based cancer (PBR) registered as the incidence date (OSP), and those with corrected dates when the delayed report dates were calibrated (OSC).ResultsAmong 2,636 cases, 1,307 had incidence dates registered in PBR prior to the diagnosis dates of the first hospitalization registered in HBR, while 667 cases with incidence dates registered in PBR were later than the diagnosis dates registered in HBR. The 5-year OSH, OSP, and OSC were 36.1%, 37.4%, and 39.0%, respectively. The “lost” proportion of 5-year survival due to the left truncation for HBR data was estimated to be between 3.5% and 7.4%, and the “delayed-report” proportion of 5-year survival for PBR data was found to be 4.1%.ConclusionLeft truncation of survival in HBR cases was demonstrated. The pseudo-left truncation in PBR should be reduced by controlling delayed reporting and maximizing completeness. Our study provides practical references and suggestions for evaluating the survival of cancer patients with HBR and PBR.

全文就中国肝癌的预防、筛检的现状,从肝癌的流行趋势、病因预防、筛检研究、防控效果等方面,总结实践经验,归纳主要进展,分析问题与挑战,并对未来肝癌防控工作的开展提出展望建议.

[目的]对2007-2017年南通市肿瘤医院乳腺癌住院病例进行生存率分析.[方法]采用以医院为基础的肿瘤随访结合现场以人群为基础的肿瘤随访方法,随访截止于2020年12月31日.以寿命表法计算观察生存率(OSR),用SPSS 22.0软件进行统计分析并绘制曲线图,采用Wilcoxon统计量Gehan值作生存率比较.[结果]2007-2017年登记乳腺癌住院病例3 315例,经随访获得癌症生存结局3 291例(随访成功率为99.28％),其中男性31例(0.94％),女性3 260例(99.06％).首次入院时平均年龄为(53.44±10.88)岁;以35～59岁为最多见(68.52％),其次为60～79岁(26.86％).每例患者平均住院(5.66±5.40)次.男性乳腺癌患者1、3、5 及 10 年 OSR 分别为 83.87％、74.19％、63.21％及 19.39％;女性患者则分别为 91.66％、79.02％、73.14％及 63.37％,差异无统计学意义(P=0.078).15～34 岁、35～59 岁、60～79 岁及 80～99 岁各年龄组 5 年 OSR 分别为 73.74％、75.71％、67.03％及 56.80％(P＜0.001).2007-2012 年及2013-2017年两个时期的5年OSR分别为69.42％及76.10％(P＜0.001).乳腺癌生存率存在地区差异.TNM分期显示Ⅰ期、Ⅱ期、Ⅲ期及Ⅳ期病例的5年OSR分别为94.30％、92.58％、71.52％及31.37％(P＜0.001)o[结论]2007-2017年乳腺癌患者以中老年女性为主,青壮年女性乳腺癌的生存率较高;分期为Ⅰ期、Ⅱ期的早期乳腺癌患者预后较好.应该加强乳腺癌的综合防治能力.

[目的]分析南通地区老年恶性肿瘤住院患者的人口学特征和历年变化趋势.[方法]从以医院为基础的癌症登记数据库中摘取2002-2017年期间60岁及以上老年恶性肿瘤患者记录,按性别、年龄、入出院次数、户籍来源、恶性肿瘤部位等采用SPSS软件进行分类统计分析.用Cox-Staurt趋势检验评估住院患者的增长趋势.[结果]2002-2017年登记的74480例患者中,老年恶性肿瘤为40511例,占54.39％;老年恶性肿瘤患者每例平均住院2.60次.首次就诊入住的老年恶性肿瘤患者,从2002年的1319例增长到2017年的4028例,增长了205.38％.食管癌、肺癌、胃癌、宫颈癌、肝癌等住院人数前20位的恶性肿瘤中,除鼻咽癌之外,住院病例增长趋势均有统计学意义(P＜0.05).老年患者以60～64岁者为最多,其次为65～69岁组,并随年龄的增长而减少;老年患者的首次人院平均年龄,由2002年的(68.11±6.08)岁,上升到2017年的(70.17±6.84)岁.老年各年龄组历年住院数以及南通各县市区的老年住院病例数,均呈现显著的上升趋势(P＜0.05).[结论]接受人院治疗的老年恶性肿瘤病例数正在不断增长,区域性的癌症防控、专科发展应当充分考虑老龄患者的需求.

Objective:To analyze the survival rate of malignant tumor in the elderly over 60 years old in Qidong city from 1972 to 2016, and to provide basis for prognosis evaluation and prevention.Methods:Based on the data of 66 386 patients with malignant tumor in the elderly over 60 years old in the Qidong cancer registration and reporting system, the survival outcome was tracked by the method of active follow-up and passive follow-up.All of these data were then analyzed by stratification of sex, age, tumor site and hospital level.Results:During the period of 1972 to 2016, the total number of patients with malignant tumors in the elderly were 66 386 cases, accounting for 56.66% of patients in all age groups.The observed survival rate(OSR)of 5 and 10 years were 14.52% and 9.53% and relative survival rate(RSR)of 5 and 10 years were 19.76% and 18.92%, respectively, in the elderly in Qidong.The 5-year RSR was 16.98% for males and 23.91% for females, being a statistically significant( χ2=339.83, P<0.001). The 5-year RSRs of elderly patients in males and females increased from 7.53% and 15.83% in 1972-1976 to 28.06% and 39.01% in 2012-2016, respectively.The 5-year RSR of 60-64, 65-69, 70-74, 75-79, 80-84 and 85 years old and over were 22.84%, 20.53%, 17.74%, 18.30%, 18.02% and 14.06%, respectively, with a statistically significant difference( χ2=694.27, P<0.001). Among the top 10 major malignancies, the ranks of 5-year RSR from high to low were breast cancer, prostate cancer, bladder cancer, colorectal cancer, malignant lymphoma, gastric cancer, liver cancer, esophageal cancer, lung cancer, and pancreatic cancer, respectively.A comparison between 2002--2016 and 1972--1986 showed that the increased rank of absolute values of RSR from highest to lowest were prostate cancer, colorectal cancer, female breast cancer, bladder cancer, gastric cancer, malignant lymphoma, liver cancer, esophageal cancer, lung cancer, and pancreatic cancer, respectively.The 5-year RSR of patients diagnosed in the district / township hospitals, county hospitals, city-level 3A hospitals and provincial-level 3A hospitals were 13.97%, 23.71%, 26.12% and 28.55%, respectively, with a statistically significant difference( χ2=841.93, P<0.001). In the 45 years, the average annual percentage change(AAPC)ratio of 5-year OSR was 3.88%( t=6.75, P<0.001), and the 5-year RSR was 3.69%( t=7.44, P=0.001); the AAPC of the 5-year RSR was 3.91%( t=9.66, P<0.001)in males and 3.42%( t=6.08, P=0.001)in females.The AAPC ratio of 5-year RSR in each age group were 4.08% for 60-64 years, 4.18% for 65-69 years, 3.91% for 70-74 years, 3.12% for 75-79 years, 3.81% for 80-84 years, 0.51% for 85 years old and over, respectively.Except for age group of 85 years old and over( P=0.615), significant rising trends were observed in all age groups( P<0.01). Conclusions:Malignant tumors in the elderly have become the major cancer burden in Qidong, and there are significant gender and age differences.The overall survival rate in elderly patients with malignant tumors has been significantly improved in the past 45 years, which may be related to the improvement in the level of diagnosis and treatment and the service capacity of hospitals.

目的 对南通市肿瘤医院2002—2017年鼻咽癌病例临床资料进行分析,了解南通地区鼻咽癌分布流行特点,为鼻咽癌早诊筛查和制定综合防治措施提供参考信息.方法 收集南通市肿瘤医院2002年1月—2017年12月肿瘤登记数据库中319例鼻咽癌患者病例资料,对鼻咽癌年龄、性别、临床症状、病程、住院次数和病理类型等变量进行统计分析.结果 319例鼻咽癌患者中,男性221例(69.28％),女性98例(30.72％).年龄最小为16岁,最大为83岁,中位年龄55岁;患者主要集中在40～69岁.住院病程中位时间为5.02个月,超过6个月者占50.47％.患者临床症状中,43.57％为鼻部症状,40.44％伴发有颈部肿物.TNM分期中,T1～T2共124例(38.87％),T3～T4共103例(32.29％);N0共33例(10.34％),N1～N2共176例(55.17％);远处复发转移(M1)为48例(15.05％).临床分期以中晚期为主,Ⅲ期最多(115例,36.05％),Ⅳ期次之(78例,37.62％).病理组织类型以非角化型未分化癌居多(98.43％).住院1次者占20.06％,住院2～5次者为53.61％,平均住院4.48±3.71次.早期病例和中晚期病例的5年观察生存率分别为77.50％和72.96％,差异有统计学意义(P<0.05).结论 住院鼻咽癌患者以男性为主、中老年人为主,非角化型未分化癌为主且以中晚期病例为主.鼻咽癌的早诊早治应引起重视.

目的:对南通市肿瘤医院2002-2014年以医院为基础的肿瘤登记胃癌病例作生存率分析,为综合评估胃癌患者预后提供依据.方法:采用主动随访与被动随访相结合的方法,对癌症登记数据库中来自启东、海门籍的胃癌住院患者进行生存结局的随访.用寿命表法计算观察生存率,并采用SPSS 26软件作生存率比较分析,Wilcoxon统计量Gehan值评估差异的显著性.结果:启东、海门籍胃癌患者428例,失访13例(3.04％),获得癌症生存结局信息者为415例(随访率为96.96％),其中男性278例,女性137例,首次入院平均年龄为61.86±11.99岁,60岁以上老年人共计256例,占59.81％.患者的1年、3年、5年及10年观察生存率分别为51.08％、27.80％、21.62％及18.06％.除1年生存率外,男性2～10年生存率均低于女性生存率,但差异无统计学意义(Wilcoxon统计量Gehan=0.085,P=0.770).0～39岁组、40～49岁组、50～59岁组、60～69岁组及≥70岁组的5年总观察生存率分别为33.89％、19.68％、25.23％、23.33％及16.19％,差异无统计学意义.启东籍胃癌患者1～5年观察生存率略高于海门籍患者,而5年以上观察生存率则稍低于海门籍患者,但两组间比较差异无统计学意义(Wilcoxon统计量Gehan=0.317,P=0.573).结论:胃癌患者生存率的性别差异、年龄别差异及地区差异不显著.与发达国家或地区相比,胃癌的总体生存率有待提高.

Background:EH domain contains protein 2 (EHD2) may be involved in tumorigenesis and development. However, the role of EHD2 in lung adenocarcinoma (LUAD) is unknown.Methods:The link between EHD2 and LUAD and the associated underlying mechanism was determined using bioinformatics analysis. Then, immunohistochemistry (IHC) was employed to detect EHD2 expression level in LUAD patients. The stable transfection cell line was used to establish with lentivirus vector, and then the transfection efficiency was detected by western blot. Phagokinetic motility assays, transwell assays, and western blotting were also employed to investigate EHD2 impacts on cell viability.Results:The results indicated that EHD2 protein expression in human LUAD samples was significantly lower than that in the adjacent normal tissues. Low EHD2 expression was significantly linked to lymph node metastasis as well as advanced tumor-node-metastasis (TNM) staging (P<0.05). The Kaplan-Meier survival curve showed that low EHD2 expression was significantly associated with low survival (P=0.01). The multivariate Cox regression analysis confirmed that EHD2 expression and TNM stage were independent prognostic factors for LUAD patients (all P<0.05). The in vitro experiments demonstrated that EHD2 knockdown markedly contributed to an increase in migration and invasion in A549 cells. Overexpression of EHD2 substantially suppressed H1299 cell migration and invasion. Furthermore, decreased E-cadherin expression was observed in A549 cells with EHD2 knockdown, as well as increased N-cadherin and vimentin expressions. By contrast, E-cadherin expression was increased in H1299 cells, whereas N-cadherin and vimentin expressions were decreased as a result of EHD2 overexpression.Conclusions:Our study demonstrated that EHD2 reduces LUAD migration and invasion by preventing the epithelial-mesenchymal transition (EMT) process. Furthermore, the results suggest that EHD2 may be a novel biomarker for prognosis prediction.

Objective The association between ABO blood group and risk of liver cancer is unclear, although few studies have reported positive results. This study examined the relationship between ABO blood group and liver cancer in hepatitis B surface antigen (HBsAg)-positive individuals.Design A high-risk population-based cohort study.Setting The study was started in 2007 and closed in 2019; the number of observed person-years as obtained by ABO blood group.Participants The study included 3663 individuals with positive HBsAg, including men aged 30–70 and women aged 40–70.Outcome measures The frequencies of ABO group in the cohort population and patients with liver cancer were calculated, respectively. χ2 test was used to compare differences, and the relative risk (95% CI) for development of liver cancer was evaluated.Results The frequency distribution of blood types A, B, O and AB was 1118 (30.52%), 1073 (29.29%), 1104 (30.14%) and 368 (10.05%), respectively, among 3663 cohort individuals. In the cohort, patients with liver cancer (n=336) were of the following frequencies: type A: 104 (30.95%); type B: 97 (28.87%); type O: 95 (28.27%); and type AB: 40 (11.90%). No significant difference was found between patients with liver cancer and other individuals. The annual incidence rate of liver cancer was 906.34 per 100 000 person-years, and for blood type A, B, O and AB the rates were 917.76, 893.78, 846.02 and 1093.43 per 100 000 person-years, respectively. The relative risk (95% CI) was 0.97 (0.74 to 1.29), 0.92 (0.70 to 1.22) and 1.19 (0.82 to 1.72) for blood types B, O and AB, respectively, compared with blood type A.Conclusion There were no significant differences in the frequency distribution of ABO blood groups in patients with liver cancer within this high-risk cohort, which demonstrates lack of positive association between ABO blood group and risk of liver cancer.

BACKGROUND AND AIMS:To explore the long-term trend of liver cancer survival, based on the real-world data (RWD) in the past 45 years from a population-based cancer registry, in Qidong, China. METHODS:A number of 32,556 patients with liver cancer were registered during the period of 1972 to 2016. Mixed methods by active and passive follow-up were performed. Life table method was employed for survival analysis by SPSS22 software. Wilcoxon (Gehan) statistics was considered as a significant test. Relative survival was calculated by using SURV software, and its annual percent change (APC) was estimated by the Joinpoint Regression Program. RESULTS:The overall observed survival (OS) rates of 1-, 5-, 10-, and 20-year rates from the data series were 18.51%, 6.28%, 4.03%, and 2.84%, and their relative survival (RS) rates were 18.88%, 6.95%, 4.96%, and 4.49%, respectively. For 24,338 male cases, the 5-year OS and RS rates were 5.93% and 6.54%, and for 8218 female cases, 7.34% and 8.15%, respectively, with P values less than 0.01. Survival rates of liver cancer from three 15-year periods of 1972-1986, 1987-2001, and 2002-2016 have increased significantly, with 5-year OS rates of 2.02%, 4.40%, and 10.76%, 5-year RS rates of 2.18%, 4.83%, and 12.18%; 10-year OS and RS rates of 0.95%, 3.00%, and 7.02%, vs 1.13%, 3.65%, and 8.96%, respectively, showing a very significant upward trend (P<0.01). There are significant differences among age groups (P<0.01): those aged 55-64 demonstrated the best OS and RS rates of 5-year, being 8.44% and 9.09%, respectively. CONCLUSION:There are significant gender and age differences in the survival rate of liver cancer in Qidong. RWD indicates the relative lower survival rate of liver cancer in this area, but great improvement has been achieved over the past decades.

Background and aims: Liver cancer is one of the most dominant malignant tumors in the world. The trends of liver cancer mortality over the past six decades have been tracked in the epidemic region of Qidong, China. Using epidemiological tools, we explore the dynamic changes in age-standardized rates to characterize important aspects of liver cancer etiology and prevention. Methods Mortality data of liver cancer in Qidong from 1958 to 1971 (death retrospective survey) and from 1972 to 2017 (cancer registration) were tabulated for the crude rate (CR), and age-standardized rate and age-birth cohorts. The average annual percentage change was calculated by the Joinpoint Regression Program. Results The natural death rate during 1958–2017 decreased from 9‰ to 5.4‰ and then increased to 8‰ as the population aged; cancer mortality rates rose continuously from 57/105 to 240/105. Liver cancer mortality increased from 20/105 to 80/105, and then dropped to less than 52/105 in 2017. Liver cancer deaths in 1972–2017 accounted for 30.53% of all cancers, with a CR of 60.48/105, age-standardized rate China (ASRC) of 34.78/105, and ASRW (world) of 45.71/105. Other key features were the CR for males and females of 91.86/105 and 29.92/105, respectively, with a sex ratio of 3.07:1. Period analysis showed that the ASRs for mortality of the age groups under 54 years old had a significant decreasing trend. Importantly, birth cohort analysis showed that the mortality rate of liver cancer in 40–44, 35–39, 30–34, 25–29, 20–24, 15–19 years cohort decreased considerably, but the rates in 70–74, and 75+ increased. Conclusions The crude mortality rate of liver cancer in Qidong has experienced trends from lower to higher levels, and from continued increase at a high plateau to most recently a gradual decline, and a change greatest in younger people. Many years of comprehensive prevention and intervention measures have influenced the decline of the liver cancer epidemic in this area. The reduction of intake levels of aflatoxin might be one of the most significant factors as evidenced by the dramatic decline of exposure biomarkers in this population during the past three decades.

Background: The novel coronavirus pneumonia (COVID-19) has been global threaten to public health. This paper provides perspective to the decision-making for public health control of the pandemic or the spread of epidemic. Methods: According to the WHO global reported database, we developed and used the number of cumulative cases, and the number of cumulative deaths to calculate and analyze rates of incidence, mortality, and fatality by country, with respect to the 30 highest outbreak (Top 30) countries. Results： As of December 31, 2020, of the global population of 7.585 billion, the cumulative number of reported cases was 81,475,053, and the cumulative number of deaths was 1,798,050. The incidence rate of COVID-19 was 1074.13 per 100,000 population, the mortality rate was 23.70 per 100,000, and the case fatality rate was 2.21%. Among the Top 30 countries, the five countries with the highest number of reported cumulative cases were, in rank, the United States (19,346,790 cases), India (10,266,674), Brazil (7,563,551), Russia (3,159,297) and France (2,556,708), and the five countries with the highest number of cumulative deaths were the United States (335,789 cases), Brazil (192,681), India (148,738), Mexico (123,845) and Italy (73,604). Globally, the countries with the highest incidence rate were, in rank, Andorra, Luxembourg, Montenegro, San Marino, and Czechia; the countries with the highest mortality rate were, in rank, San Marino, Belgium, Slovenia, Italy, and North Macedonia. The highest fatality rate was found in Yemen, Mexico, Montserrat, Isle of Man, and Ecuador, respectively. In China, 96,673 cases of COVID-19 and 4788 deaths were reported in 2020, ranking the 78th and the 43 rd , respectively, in the world. The incidence rate and mortality rate were 6.90/10 5 and 0.34/10 5 , respectively, ranking 207th and 188th in the world. The case fatality rate was 4.95%, ranking 11th in the world. Conclusions： The COVID-19 prevalence is still on the rise, and the turning points of incidence and mortality are not yet forecasted. Personal protection, anti-epidemic measures and efforts from public health personnel, medical professionals, biotechnology R&D personnel, effectiveness of the vaccination programs and the governments, are the important factors to determine the future prevalence of this coronavirus disease.

Background: The incidence and mortality rates of hepatocellular carcinoma (HCC) are increasing worldwide. Therefore, there is an urgent need to elucidate the molecular drivers of HCC for potential early diagnosis and individualized treatment. Whether c-Myc expression plays a role in the clinicopathology and prognosis of patients with HCC remains controversial. This meta-analysis aimed to survey the prognostic role of c-Myc in HCC. Methods: We searched PubMed, Cochrane Library, Embase, Web of Science, and Google Scholar databases for studies published through March 2020 that examined the association between c-Myc expression and clinicopathology or prognosis in HCC patients. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to investigate the prognostic significance of c-Myc expression. Odds ratios were calculated to evaluate the association between c-Myc expression and clinicopathologic features. We also tested for publication bias. Results: Our meta-analysis included nine studies with 981 patients with HCC published between 1999 and 2016. A meta-analysis of these studies demonstrated that high c-Myc expression indicated a poor overall survival (OS) (HR = 2.260, 95% CI: 1.660–3.080, and p < 0.001) and disease-free survival (DFS) (HR = 1.770, 95% CI: 1.430–2.450, and p < 0.001) in patients with HCC. However, high c-Myc expression was not associated with HBsAg, pathological type, TNM stage, or cirrhosis. We did not find any significant publication bias among the included studies, indicating that our estimates were robust and reliable. Conclusion: c-Myc overexpression could predict poor OS and DFS in HCC patients. c-Myc could be a useful prognostic biomarker and therapeutic target for HCC.

目的:了解南通市某三甲医院从事肿瘤护理的专业人员营养知识、态度和行为现状及影响因素.方法:对入选人员普查,计算得分(x-±s)、构成比,进行t检验、单因素方差分析、多元逐步回归等.结果:疾病营养知识得分高于基础营养(P=0.009),营养知识得分在学历(P=0.001)、职称(P=0.024)方面差异有统计学意义,中专学历、副主任护师及以上职称者在营养知识得分方面较高,营养态度和营养行为得分在科室分布上有差异.营养态度、学历、职称影响营养知识得分,营养知识和营养行为对态度有影响,营养态度是营养行为的影响因素.结论:南通市某三甲医院肿瘤专业护理人员总体营养知信行水平较高,营养基础知识有待加强,营养知信行相互影响,可加强学校营养教育和在职继续教育提高营养素养.

全文分析以医院为基础的肿瘤登记系统资料收集过程中的常见问题,为全国开展以医院为基础的肿瘤登记工作提供参考和借鉴.在将医院HIS系统数据转化为肿瘤登记数据库的过程中,对患者住院号、身份证号码、地址信息、联系方式、出院主诊断、主诊断与肿瘤登记部位确定、复合癌与多原发肿瘤等方面的共性问题进行归纳、辨析,提出应对建议,推动以医院为基础的肿瘤登记工作更好发展.